All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2016-09-26T15:20:11.000Z

4th International Conference on Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment

Sep 26, 2016
Share:

Bookmark this article

The European School of Hematology (ESH) is a not-for-profit institution dedicated to increasing knowledge in hematology and related disciplines at the European level.  The ESH Conferences are known for their state-of-the-art science and new developments in hematology.

The next conference on “Molecular and Translational advances in Biology and Treatment” is chaired by international experts in AML including two members of the AGP steering committee, Dr H. Döhner (Germany) and Dr M. Tallman (USA).

The conference will focus on the molecular techniques, which are creating novel insights into the biology and therapeutic perspectives of AML. Molecular diagnosis, genomic and epigenetic studies have allowed a better understanding of the pathobiology of the disease and identification of major pathways of malignant transformation leading to development of novel therapeutic approaches.

There will be expert panel sessions, poster sessions and a varied scientific programme. This conference promises to be a cutting-edge event in the field of hematology.

 The event will take place on October 5th - 7th, 2017 in Estoril, Portugal

 For more information please visit the ESH website here

More about...

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox